Pancreatic cancer is an increasingly lethal cancer and is often diagnosed at an advanced stage. Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic malignant tumors and is known as the "king of cancers". The degree of malignancy is very high, making diagnosis and treatment difficult. This is because pancreatic ductal adenocarcinoma tissue contains a large amount of fibrous tissue in addition to ductal epithelial cell components. The existence of fibrous tissue results in poor blood supply for pancreatic cancer, making it difficult for chemotherapy drugs to enter, so the treatment effect is not ideal. So there is a need to develop new and more effective treatments to cure this disease.
Pancreatic Cancer Antibodies We Offer
Antibodies can be used to target cancer cells and prevent tumor growth and progression. Antibodies have been widely used in malignant tumor research, such as pancreatic cancer, breast cancer, colon cancer, non-small cell lung cancer, etc. Clinical studies have shown that antibody therapy can not only effectively kill focus cells, but also activate the human immune system to improve the body's defense against cancer, while reducing treatment side effects and improving patient survival rates. The essence of antibody therapy is to use specific monoclonal antibodies synthesized in vitro to achieve the purpose of treatment by identifying, binding and eliminating disease-related antigens or disease cells expressing antigens. Alfa Cytology has extensive experience in pancreatic cancer research and can provide you with antibody products suitable for your research project.
Alfa Cytology is committed to providing customers with antibody products with strong targeting, high stability, and obvious effects for pancreatic cancer research. We can recommend the best antibody options based on our customers' needs. If you are interested in our products, please contact us for more details.
CDK1-IN-5
Catalog No.: PC0183
Description: CDK1-IN-5 (10h) is a selective CDK1 inhibitor with IC50 values of 42.19, 188.71, and 354.15 nM for CDK1, CDK2, and CDK5, respectively. CDK1-IN-5 inhibits the growth of cancer cells by affecting the cell cycle.
CDK1-IN-3
Catalog No.: PC0184
Description: CDK1-IN-3 (8g) is a selective CDK1 inhibitor with IC50 values of 36.8, 305.17, and 369.37 nM for CDK1, CDK2, and CDK5, respectively. CDK1-IN-3 inhibits the growth of cancer cells by affecting the cell cycle.
CDK1-IN-4
Catalog No.: PC0185
Description: CDK1-IN-4 (10d) is a selective CDK1 inhibitor with IC50 values of 44.52, 624.93, and 135.22 nM for CDK1, CDK2, and CDK5, respectively. CDK1-IN4 inhibits the growth of cancer cells by affecting the cell cycle.
CR-1-31-B
Catalog No.: PC0186
Description: CR-1-31-B is a synthetic rocaglate and a potent eIF4A inhibitor that blocks the initiation of protein synthesis by interfering with the interaction between eIF4A and RNA.
N6F11
Catalog No.: PC0187
Description: N6F11 is a ferroptosis inducer, and can trigger the degradation of glutathione peroxidase 4 (GPX4) specifically in cancer cells. N6F11 can be used for ferroptosis study.
Chlorin e6
Catalog No.: PC0188
Description: Chlorin e6 is a photosensitizer and has strong absorption peaks at wavelength of 402 and 662 nm, as well as exhibiting intense fluorescence at 668 nm. Chlorin e6 has antimicrobial efficacy and anticancer activity. Chlorin e6 induces cell apoptosis via caspase-3 activation and can be used for the research of cancer.
PNC-28 acetate
Catalog No.: PC0189
Description: PNC-28 acetate is a peptide derived from the mdm-2 binding domain (residues 17-26) of the p53 protein and contains a transmembrane penetrating sequence. PNC-28 acetate could be used in pancreatic cancer research.
Targefrin
Catalog No.: PC0190
Description: Targefrin is a potent EphA2-targeting agent, acts as an antagonist. Targefrin binds EphA2-LBD with 21 nM dissociation constant and an IC50 value of 10.8 nM. Targefrin induces cellular receptor internalization and degradation in several pancreatic cancer cell lines.
Elpamotide
Catalog No.: PC0191
Description: Elpamotide is an epitope peptide derived from VEGFR2. Elpamotide induces cytotoxic T lymphocytes (CTL) to kill VEGFR2-expressing endothelial cells. Elpamotide has potential immunostimulatory and antitumor activity. Ipamotide is used in cancer research, such as pancreatic cancer.
PNC-28
Catalog No.: PC0192
Description: PNC-28 is a peptide derived from the mdm-2 binding domain (residues 17-26) of the p53 protein and contains a transmembrane sequence. PNC-28 can be used in pancreatic cancer research.
Ederimotide
Catalog No.: PC0193
Description: Ederimotide(WT-1 A1) can be used as a potential target for studying pancreatic cancer.